Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Capricor Therap (CAPR)

Capricor Therap (CAPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy GlobeNewswire - Tue Dec 16, 3:05PM CST

– Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET – SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing...

CAPR : 29.68 (+2.70%)
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock GlobeNewswire - Fri Dec 5, 5:15AM CST

SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing...

CAPR : 29.68 (+2.70%)
Capricor Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire - Thu Dec 4, 3:01PM CST

SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the commencement...

CAPR : 29.68 (+2.70%)
A glass jar full of pennies_ Image by John Brueske via Shutterstock_
This ‘Strong Buy’ Penny Stock Just More Than Quadrupled on Clinical Trial Results. Should You Buy It Here? Barchart - Thu Dec 4, 9:06AM CST

Capricorn Therapeutics stock soared after the biotech firm announced positive deramiocel Phase 3 trial results. But CAPR shares still have major risks tied to them heading into 2026.

CAPR : 29.68 (+2.70%)
Financial Markets Wall Street
Wall Street pulls near its all-time high Associated Press - Wed Dec 3, 3:47PM CST

U.S. stocks rose near their record levels

NVDA : 188.61 (-0.32%)
$SPX : 6,932.05 (+0.32%)
DLTR : 122.01 (+2.07%)
MDB : 435.51 (-0.37%)
AEO : 26.65 (+0.19%)
$IUXX : 25,656.15 (+0.27%)
M : 22.32 (-1.15%)
SIG : 87.01 (+1.39%)
MSFT : 488.02 (+0.24%)
PG : 144.49 (+0.91%)
$DOWI : 48,731.16 (+0.60%)
MCHP : 65.36 (+0.02%)
Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy GlobeNewswire - Wed Dec 3, 6:20AM CST

Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03...

CAPR : 29.68 (+2.70%)
Capricor: Q3 Earnings Snapshot AP - Mon Nov 10, 3:50PM CST

Capricor: Q3 Earnings Snapshot

CAPR : 29.68 (+2.70%)
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Mon Nov 10, 3:01PM CST

Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025) Pending the results of the topline data...

CAPR : 29.68 (+2.70%)
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel GlobeNewswire - Mon Nov 3, 8:15AM CST

–Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development–  SAN DIEGO,...

CAPR : 29.68 (+2.70%)

Barchart Exclusives

The 1 Riskiest Investment That Paid Off in 2025 Barchart - 23 minutes ago
Wall Street still sees triple-digit upside in this high-risk biotech bet. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot